Abbott’s CardioMEMS Hero PA Pressure Reader Approved by FDA for Remote HF Monitoring

March 2, 2026—Abbott announced FDA approval of the CardioMEMS Hero device, its next-generation pulmonary artery (PA) pressure reader to support the care of patients with heart failure (HF). Abbott will soon begin commercial release of the Hero reader in the United States, advised the press release.

According to the company, the Hero reader is a new component of its CardioMEMS HF system and is designed to work with the CardioMEMS PA sensor.

As outlined in the press release, the Hero reader incorporates new features to detect and treat HF progression. It is 60% lighter than the previous model and is designed to fit in a carry-on suitcase. The new design enables a consistent reading position—with the patient laying down—to provide reliable daily PA pressure trends.

Additionally, integrated Wi-Fi and cellular connectivity allows patients to take a reading virtually anywhere they have a signal and securely send the data to their care team. Clinicians receiving the daily data readings can see any changes in PA pressures and communicate to the patient the need for any medication or lifestyle changes to help slow HF progression, noted the company.

“Data from CardioMEMS HF system clinical trials show the positive impact the device has on reducing the risk of HF hospitalizations and cardiovascular death,” commented JoAnn Lindenfeld, MD, in Abbott’s press release. “Hero is likely to significantly enhance data acquisition and patient interactions with this life-changing technology. Hero is lighter, more comfortable, and easier to transport and use, which improves patient experience.”

Dr. Lindenfeld, who is Director of Advanced Heart Failure at Vanderbilt University Medical Center in Nashville, Tennessee, served as primary investigator for the GUIDE-HF randomized clinical trial of PA pressure monitoring with the CardioMEMS HF system, stated Abbott.